SYRE
Spyre Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Revenue Decline
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SYRE
Spyre Therapeutics, Inc.
A clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases
221 Crescent Street , Building 23 , Suite 105 , Waltham, MA 02453
--
Spyre Therapeutics, Inc., was converted from a Delaware limited liability company on December 16, 2013. The company is a biotechnology company that aims to create the next generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational treatment combinations, and precision medical approaches for patient selection. Spyre's product line includes extended half-life antibodies against α4β7, TL1A and IL-23.
Company Financials
EPS
SYRE has released its 2025 Q3 earnings. EPS was reported at -0.15, versus the expected -0.74, beating expectations. The chart below visualizes how SYRE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
